✦ LIBER ✦

Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer

✍ Scribed by Mitsiades, Constantine S. (author);Bogdanos, John (author);Karamanolakis, Dimitrios (author);Milathianakis, Constantine (author);Dimopoulos, Theodoros (author);Koutsilieris, Michael (author)

Book ID: 118647446
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 53 KB
Volume: 26
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(06)60290-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RANDOMISED CONTROLLED CLINICAL TRIAL OF

RANDOMISED CONTROLLED CLINICAL TRIAL OF A COMBINATION OF SOMATOSTATIN ANALOG AND DEXAMETHASONE PLUS ZOLEDRONATE VS. ZOLEDRONATE IN PATIENTS WITH ANDROGEN ABLATION REFRACTORY PROSTATE CANCER

✍ M. Koutsilieris; C. Mitsiades; J. Bogdanos; D. Karamanolakis; C. Milathianakis; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Combination of LHRH analog with somatost

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

✍ Meletios A. Dimopoulos; Christos Kiamouris; Dimitra Gika; Charalambos Deliveliot 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 117 KB

A combination therapy of ethinylestradio

A combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and reduces chromogranin a (CGA) levels in androgen ablation-refractory prostate cancer patients

✍ A. Sciarra; A. Pastore; G. Voria; A. Cardi; F. Di Silverio 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 237 KB

Androgen suppression therapy, in combina

Androgen suppression therapy, in combination with radiotherapy prolongs overall survival in men with clinically localised prostate cancer: Abstracted from: D’Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer. A randomized controlled trial. JAMA 2004;292:821–27.

✍ Juanita Crook 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 90 KB

A randomized, placebo-controlled trial o

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group, Uro-Oncology Clinic, Centre Hospitalier de l’Université, de Montreal, Hôpital Notre-Dame, Montréal, Québec, Canada: J Natl Cancer Inst 2002;94:1458–1468

✍ Donald L Trump 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 15 KB

A randomized, phase II trial of ketocona

A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases: Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Cox MC, Zhai S, Cremers S, Parr A, Yang X, Chen CC, Jones E, Dahut WL, Center for Cancer Research, National Cancer Institute, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD

✍ Donald L. Trump 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 37 KB